|
119 (PB107): AB801, a potent and highly selective clinical stage AXL inhibitor, sensitizes tumors to standard of care therapies |
|
|
|
Titel: |
119 (PB107): AB801, a potent and highly selective clinical stage AXL inhibitor, sensitizes tumors to standard of care therapies |
Auteur: |
Paprcka, S. Leslie, J. Jordon, J. Chinn, L. Adeojo, L. Goshayeshi, A. Flores, R. Kline, J. Jin, L. Zhou, L. Fernandez-Salas, E. |
Verschenen in: |
European journal of cancer |
Paginering: |
Jaargang 211 () nr. S1 pagina's p. |
Jaar: |
2024 |
Inhoud: |
|
Uitgever: |
Elsevier LTD. All rights reserved. |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|